Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Summary

This study will assess the safety, tolerability, and pharmacokinetics of AZD1775 (adavosertib) given orally in combination with intravenous MEDI4736 (durvalumab). Secondly, the immunogenicity, pharmacodynamics, and preliminary anti-tumour activity will be determined in patients with refractory solid tumours.

Timeline

Start

2015-12-28

Primary completion

2019-04-22

Completion

2026-02-17

Publications

• Patel MR, Falchook GS, Wang JS, Imedio ER, Kumar S, Miah K, Mugundu GM, Jones SF, Spigel DR, Hamilton EP. Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors. Target Oncol. 2025 Jan;20(1):127-138. doi: 10.1007/s11523-024-01110-8. Epub 2024 Nov 19.

Drugs

Indications